WO1997025034A1 - Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer - Google Patents
Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer Download PDFInfo
- Publication number
- WO1997025034A1 WO1997025034A1 PCT/DK1997/000007 DK9700007W WO9725034A1 WO 1997025034 A1 WO1997025034 A1 WO 1997025034A1 DK 9700007 W DK9700007 W DK 9700007W WO 9725034 A1 WO9725034 A1 WO 9725034A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- breast cancer
- enantiomer
- treatment
- phenyl
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU13671/97A AU1367197A (en) | 1996-01-11 | 1997-01-09 | Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer |
IL12488197A IL124881A0 (en) | 1996-01-11 | 1997-01-09 | Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer |
BR9706966A BR9706966A (en) | 1996-01-11 | 1997-01-09 | Use of the 1-enanciomer of a compound and process for treatment or prophylaxis of breast cancer |
EP97900199A EP0873119A1 (en) | 1996-01-11 | 1997-01-09 | Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer |
PL97328135A PL328135A1 (en) | 1996-01-11 | 1997-01-09 | Application of 1-centchromane enantiomer in production of a pharmaceutic agent for preventing or treating mammary cancers |
JP09524767A JP2001500101A (en) | 1996-01-11 | 1997-01-09 | Use of the 1-enantiomer of St. chroman for the manufacture of a pharmaceutical composition for the treatment and prevention of breast cancer |
NO983177A NO983177L (en) | 1996-01-11 | 1998-07-10 | Use of the 1-enantiomer of centroman for the preparation of a pharmaceutical composition for the treatment or prophylaxis of breast cancer |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1000096P | 1996-01-11 | 1996-01-11 | |
US60/010,000 | 1996-01-11 | ||
DK77696 | 1996-07-11 | ||
DK0776/96 | 1996-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997025034A1 true WO1997025034A1 (en) | 1997-07-17 |
Family
ID=26064631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1997/000007 WO1997025034A1 (en) | 1996-01-11 | 1997-01-09 | Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0873119A1 (en) |
JP (1) | JP2001500101A (en) |
KR (1) | KR19990077157A (en) |
AU (1) | AU1367197A (en) |
BR (1) | BR9706966A (en) |
CA (1) | CA2241462A1 (en) |
CZ (1) | CZ217198A3 (en) |
HU (1) | HUP9901633A3 (en) |
IL (1) | IL124881A0 (en) |
NO (1) | NO983177L (en) |
PL (1) | PL328135A1 (en) |
WO (1) | WO1997025034A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024032A1 (en) * | 1997-11-10 | 1999-05-20 | Novo Nordisk A/S | Transdermal delivery of 3,4-diarylchromans |
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
AU2004200099B2 (en) * | 1998-06-11 | 2006-11-02 | Endorecherche, Inc. | Medical Uses of A Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors |
US8268806B2 (en) | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
US8389548B2 (en) | 1998-06-11 | 2013-03-05 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
WO2013130832A1 (en) | 2012-02-29 | 2013-09-06 | Repros Therapeutics Inc. | Combination therapy for treating androgen deficiency |
AU2011253842B2 (en) * | 1998-06-11 | 2014-08-14 | Endorecherche Inc. | Medical Uses of a Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors |
US8835413B2 (en) | 2004-10-20 | 2014-09-16 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women |
EP2826475A1 (en) | 2007-10-16 | 2015-01-21 | Repros Therapeutics Inc. | Trans-clomiphene for treating diabetes in hypogonadal men |
WO2015135061A1 (en) | 2014-03-10 | 2015-09-17 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm |
WO2017081171A1 (en) | 2015-11-10 | 2017-05-18 | Paracrine Therapeutics Ab | Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen |
EP3178480A1 (en) | 2009-06-16 | 2017-06-14 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
US11576891B2 (en) | 2010-06-16 | 2023-02-14 | Endorecherche, Inc. | Methods of treating or preventing estrogen-related diseases |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4447622A (en) * | 1981-09-22 | 1984-05-08 | Council Of Scientific And Industrial Research Rafi Marg | Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof |
-
1997
- 1997-01-09 AU AU13671/97A patent/AU1367197A/en not_active Abandoned
- 1997-01-09 BR BR9706966A patent/BR9706966A/en not_active Application Discontinuation
- 1997-01-09 IL IL12488197A patent/IL124881A0/en unknown
- 1997-01-09 JP JP09524767A patent/JP2001500101A/en active Pending
- 1997-01-09 CA CA002241462A patent/CA2241462A1/en not_active Abandoned
- 1997-01-09 PL PL97328135A patent/PL328135A1/en unknown
- 1997-01-09 KR KR1019980705295A patent/KR19990077157A/en not_active Application Discontinuation
- 1997-01-09 HU HU9901633A patent/HUP9901633A3/en unknown
- 1997-01-09 CZ CZ982171A patent/CZ217198A3/en unknown
- 1997-01-09 WO PCT/DK1997/000007 patent/WO1997025034A1/en not_active Application Discontinuation
- 1997-01-09 EP EP97900199A patent/EP0873119A1/en not_active Withdrawn
-
1998
- 1998-07-10 NO NO983177A patent/NO983177L/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4447622A (en) * | 1981-09-22 | 1984-05-08 | Council Of Scientific And Industrial Research Rafi Marg | Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof |
Non-Patent Citations (1)
Title |
---|
INT. J. CANCER, Volume 43, 1989, N.C. MISRA et al., "Centchroman-A Non-Steroidal Anti-Cancer Agent for Advanced Breast Cancer: Phase-II Study", pages 781-783. * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024032A1 (en) * | 1997-11-10 | 1999-05-20 | Novo Nordisk A/S | Transdermal delivery of 3,4-diarylchromans |
EP2386305A2 (en) | 1998-06-11 | 2011-11-16 | Endorecherche Inc. | Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues |
EP2399582A1 (en) | 1998-06-11 | 2011-12-28 | Endorecherche Inc. | Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues |
EP1083905B1 (en) * | 1998-06-11 | 2005-11-02 | Endorecherche Inc. | Medical use of a selective estrogen receptor modulator in combination with a sex steroide precursor |
AU2004200099B2 (en) * | 1998-06-11 | 2006-11-02 | Endorecherche, Inc. | Medical Uses of A Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors |
US7429576B2 (en) | 1998-06-11 | 2008-09-30 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US7943603B2 (en) | 1998-06-11 | 2011-05-17 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US6670346B1 (en) | 1998-06-11 | 2003-12-30 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
AU2011253842B2 (en) * | 1998-06-11 | 2014-08-14 | Endorecherche Inc. | Medical Uses of a Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors |
EP2386304A2 (en) | 1998-06-11 | 2011-11-16 | Endorecherche Inc. | Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues |
US8188066B2 (en) | 1998-06-11 | 2012-05-29 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US8389548B2 (en) | 1998-06-11 | 2013-03-05 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US10076525B2 (en) | 2004-10-20 | 2018-09-18 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of dyspareunia in postmenopausal women |
US10478443B2 (en) | 2004-10-20 | 2019-11-19 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of sexual dysfunction in postmenopausal women |
US8835413B2 (en) | 2004-10-20 | 2014-09-16 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women |
US8629129B2 (en) | 2007-08-10 | 2014-01-14 | Endorecherche, Inc. | Pharmaceutical compositions |
US8957054B2 (en) | 2007-08-10 | 2015-02-17 | Endorecherche, Inc. | Pharmaceutical compositions |
US10881650B2 (en) | 2007-08-10 | 2021-01-05 | Endorecherche, Inc. | Pharmaceutical compositions |
US8268806B2 (en) | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
EP2826475A1 (en) | 2007-10-16 | 2015-01-21 | Repros Therapeutics Inc. | Trans-clomiphene for treating diabetes in hypogonadal men |
EP3682880A1 (en) | 2009-06-16 | 2020-07-22 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
US11452731B2 (en) | 2009-06-16 | 2022-09-27 | Endorecherche, Inc. | Method of treating and preventing loss of cognition |
EP3178480A1 (en) | 2009-06-16 | 2017-06-14 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
US10342805B2 (en) | 2009-06-16 | 2019-07-09 | Endorecherche, Inc. | Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators |
US11576891B2 (en) | 2010-06-16 | 2023-02-14 | Endorecherche, Inc. | Methods of treating or preventing estrogen-related diseases |
WO2013130832A1 (en) | 2012-02-29 | 2013-09-06 | Repros Therapeutics Inc. | Combination therapy for treating androgen deficiency |
US10548903B2 (en) | 2014-03-10 | 2020-02-04 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
US9744177B2 (en) | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
WO2015135061A1 (en) | 2014-03-10 | 2015-09-17 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm |
WO2017081171A1 (en) | 2015-11-10 | 2017-05-18 | Paracrine Therapeutics Ab | Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen |
Also Published As
Publication number | Publication date |
---|---|
HUP9901633A3 (en) | 2000-02-28 |
AU1367197A (en) | 1997-08-01 |
IL124881A0 (en) | 1999-01-26 |
CA2241462A1 (en) | 1997-07-17 |
BR9706966A (en) | 1999-05-04 |
PL328135A1 (en) | 1999-01-18 |
EP0873119A1 (en) | 1998-10-28 |
KR19990077157A (en) | 1999-10-25 |
NO983177L (en) | 1998-07-10 |
JP2001500101A (en) | 2001-01-09 |
CZ217198A3 (en) | 1998-11-11 |
HUP9901633A2 (en) | 1999-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meites | Relation of prolactin and estrogen to mammary tumorigenesis in the rat | |
US8609695B2 (en) | Methods of treating and/or suppressing insulin resistance | |
EP0873122B1 (en) | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of prostatic carcinoma | |
EP0873119A1 (en) | Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer | |
JP2000506508A (en) | Use of 3,4-diphenylchroman for the manufacture of a pharmaceutical composition for the treatment or prevention of benign prostatic hyperplasia | |
JPH10511962A (en) | Use of 3,4-diphenylchroman for the manufacture of a pharmaceutical composition for treating or preventing gynecological diseases | |
KR19990077156A (en) | Use of 3,4-diphenylchrome for the preparation of pharmaceutical compositions for the treatment or prevention of menopausal symptoms | |
CA2180178C (en) | Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis | |
EP0804189A1 (en) | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment | |
US5886021A (en) | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis | |
US5780502A (en) | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome | |
WO1998033500A1 (en) | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting senescence-associated motor impairment | |
JP2000514441A (en) | Use of 3,4-diphenylchroman for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome | |
CN1207037A (en) | Use of the L-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer | |
CN1207038A (en) | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms | |
WO1999048497A1 (en) | USE OF 3,4-DIPHENYLCHROMANS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR LOWERING PLASMA LEVELS OF Lp(a) IN A HUMAN OR SUB-HUMAN PRIMATE | |
MXPA97005214A (en) | Use of the 3,4-difenil-chromanos for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia or arterioesclerosis or for anti-treatment | |
WO1998034608A1 (en) | Methods for treatment or prophylaxis of menopausal symptoms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97191644.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997900199 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2241462 Country of ref document: CA Ref document number: 2241462 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1998/005479 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 1997 524767 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1998-2171 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980705295 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1997900199 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1998-2171 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980705295 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997900199 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1998-2171 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019980705295 Country of ref document: KR |